Related references
Note: Only part of the references are listed.The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis
Sanne E. Franck et al.
NEUROENDOCRINOLOGY (2017)
Pegvisomant Treatment in Acromegaly
Sebastian J. C. M. M. Neggers et al.
NEUROENDOCRINOLOGY (2016)
Bone and Joint Disorders in Acromegaly
Kim M. J. A. Claessen et al.
NEUROENDOCRINOLOGY (2016)
Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY
Aart Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Current and Emerging Aspects of Diabetes Mellitus in Acromegaly
Stefano Frara et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Treatment of acromegaly in the era of personalized and predictive medicine
Manuel Puig Domingo
CLINICAL ENDOCRINOLOGY (2015)
X-linked acrogigantism syndrome: clinical profile and therapeutic responses
Albert Beckers et al.
ENDOCRINE-RELATED CANCER (2015)
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
Emmanuelle Kuhn et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3
S. E. Franck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort
Caroline Sievers et al.
PITUITARY (2015)
Influence of growth hormone receptor (GHR) exon 3 and-202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly
Raquel S. Jallad et al.
PITUITARY (2015)
Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience
S. Cannavo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?
Andrea Giustina et al.
ACTA DIABETOLOGICA (2015)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Pregnancy in acromegaly patients treated with pegvisomant
A. J. van der Lely et al.
ENDOCRINE (2015)
ACROSTUDY: the Italian experience
S. Grottoli et al.
ENDOCRINE (2015)
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study
Gemma Sesmilo et al.
CLINICAL ENDOCRINOLOGY (2014)
Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels
Michael Droste et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Acromegaly and pregnancy: a prospective study
Monike Dias et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors
Andrea Giustina et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Acromegaly and pregnancy: Report of six new cases
M. -L. Persechini et al.
JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION (2014)
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Prospective Study of Surgical Treatment of Acromegaly: Effects on Ghrelin, Weight, Adiposity, and Markers of CV Risk
Carlos Reyes-Vidal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Biochemical and quality of life responses to octreotide-LAR in acromegaly
Ruth Mangupli et al.
PITUITARY (2014)
Impact of treatment satisfaction on quality of life of patients with acromegaly
Hasan Kepicoglu et al.
PITUITARY (2014)
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2014)
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status
Rosario Pivonello et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Octreotide for acromegaly treatment: a reappraisal
Andrea Giustina et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study
G. Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Antonio Bianchi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
A consensus on the diagnosis and treatment of acromegaly complications
S. Melmed et al.
PITUITARY (2013)
The role of combination medical therapy in acromegaly: hope for the nonresponsive patient
Maria Fleseriu
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2013)
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature
Sonia Cheng et al.
CLINICAL ENDOCRINOLOGY (2012)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
Leandro Kasuki et al.
ENDOCRINE-RELATED CANCER (2012)
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study
M. Filopanti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Pregnancy and acromegaly: a review
Vicky Cheng et al.
PITUITARY (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity
J. Roemmler et al.
SLEEP AND BREATHING (2012)
Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays
David R. Clemmons
CLINICAL CHEMISTRY (2011)
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy
Gherardo Mazziotti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Combination treatment with somatostatin analogues and pegvisomant in acromegaly
S. J. C. M. M. Neggers et al.
GROWTH HORMONE & IGF RESEARCH (2011)
Inhibition of Growth Hormone Receptor Activation by Pegvisomant may Increase Bone Density in Acromegaly
C. Jimenez et al.
HORMONE AND METABOLIC RESEARCH (2011)
Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study
M. Marazuela et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients
Michael Madsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COMETA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group
E. De Menis et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2011)
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Maria Fleseriu
PITUITARY (2011)
Effects of octreotide exposure during pregnancy in acromegaly
Pietro Maffei et al.
CLINICAL ENDOCRINOLOGY (2010)
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed
Tirissa J. Reid et al.
CLINICAL ENDOCRINOLOGY (2010)
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Ignacio Bernabeu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Female Gonadal Function before and after Treatment of Acromegaly
Michael Grynberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women
Philippe Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Long-term experience of pegvisomant therapy as a treatment for acromegaly
C. E. Higham et al.
CLINICAL ENDOCRINOLOGY (2009)
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
Peter J. Trainer et al.
CLINICAL ENDOCRINOLOGY (2009)
Subcutaneous lipoatrophy induced by long-term pegvisomant administration
Cannavo Salvatore et al.
CLINICAL ENDOCRINOLOGY (2009)
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy
Monica Marazuela et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Successful use of weekly pegvisomant administration in patients with acromegaly
C. E. Higham et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Andrea Giustina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
ACROSTUDY: the first 5 years
Peter J. Trainer
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly
C. Berg et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
The German ACROSTUDY: past and present
M. Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly
Antonio Bianchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Pegvisomant Improves Insulin Sensitivity and Reduces Overnight Free Fatty Acid Concentrations in Patients with Acromegaly
C. E. Higham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
E. Ghigo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
Antonio Bianchi et al.
PITUITARY (2009)
Alterations in body composition in acromegaly
Laurence Katznelson
PITUITARY (2009)
Pegvisomant increases intra-abdominal fat in patients with acromegaly:: a pilot study
U. Ploeckinger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease
Maria Vittoria Davi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
Maria P. Matta et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Lipodystrophy in patients with acromegaly receiving pegvisomant
Vivien S. Bonert et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Prevalence of Vertebral Fractures in Men with Acromegaly
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The management of the patient with acromegaly and headache: A still open clinical challenge
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2008)
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2008)
Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly
Gregory A. Kaltsas et al.
CLINICAL ENDOCRINOLOGY (2007)
Pegvisomant-induced lipohypertrophy:: Report of a case with histopathology
Monica Marazuela et al.
ANNALS OF INTERNAL MEDICINE (2007)
Health-related quality of life in AcroBel, the Belgian Registry acromegalic subjects: data from on acromegaly
Guy T'Sjoen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Treatment of acromegaly with pegvisomant during pregnancy: Maternal and fetal effects
Susan Riddle Brian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly
Rune Lindberg-Larsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy
Donghua Yin et al.
CLINICAL CANCER RESEARCH (2007)
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant
Craig Parkinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
IVF/ICSI in a woman with active acromegaly: Successful outcome following treatment with pegvisomant
Asjid Qureshi et al.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS (2006)
Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant
Pietro Maffei et al.
ANNALS OF INTERNAL MEDICINE (2006)
Skin manifestations in acromegaly
Anat Ben-Shlomo et al.
CLINICS IN DERMATOLOGY (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: Effects on cardiovascular risk factors
CL Ronchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Resistance to somatostatin analogs in acromegaly: An evolving concept?
M Gola et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women
S Bonadonna et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant
AL Barkan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Predictors and rates of treatment-resistant tumor growth in acromegaly
GM Besser et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly
BL Herrmann et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant
WM Drake et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly
C Parkinson et al.
CLINICAL ENDOCRINOLOGY (2003)
Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly
ML Jaffrain-Rea et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal
C Parkinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Growth hormone receptor antagonist improves insulin resistance in acromegaly
DR Rose et al.
GROWTH HORMONE & IGF RESEARCH (2002)
Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
JJ Kopchick et al.
ENDOCRINE REVIEWS (2002)
Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly:: development and psychometric properties
SM Webb et al.
CLINICAL ENDOCRINOLOGY (2002)
Human placental growth hormone - A review
MC Lacroix et al.
PLACENTA (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Effect of Sandostatin® LAR® on sleep apnoea in acromegaly:: correlation with computerized tomographic cephalometry and hormonal activity
MSM Ip et al.
CLINICAL ENDOCRINOLOGY (2001)
Successful treatment of resistant acromegaly with a growth hormone receptor antagonist
WM Drake et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Octreotide LAR® treatment throughout pregnancy in an acromegalic woman
M Fassnacht et al.
CLINICAL ENDOCRINOLOGY (2001)
Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study
L Katznelson et al.
CLINICAL ENDOCRINOLOGY (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
